Stocktoria
Grace Therapeutics, Inc. GRCE
Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2013-03-07
Grace Therapeutics, Inc. financials (annual)
Bars are annual figures from 2019 to 2026; red bars are negative (a loss or cash outflow).
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | $100.0M | $196,000 | — | — |
| R&D expense | $2.4M | $9.5M | $4.7M | $10.0M | $5.6M | $4.2M | $16.0M | $29.4M |
| Operating income | -$11.1M | -$16.7M | -$12.9M | -$52.2M | -$15.6M | -$16.4M | -$24.4M | -$34.4M |
| Income tax | -$1.7M | -$3.2M | -$1.8M | -$9.5M | -$648,000 | $0 | $0 | $0 |
| Net income | -$7.8M | -$9.6M | -$12.9M | -$42.4M | -$9.8M | -$19.7M | -$25.5M | -$39.4M |
| EPS (diluted) | $-0.47 | $-0.79 | $-1.35 | $-5.71 | $-0.27 | — | — | — |
| Operating cash flow | -$8.9M | -$14.9M | -$12.3M | -$15.9M | -$17.2M | -$14.3M | -$23.0M | — |
| Cash & equivalents | $17.0M | $22.1M | $23.0M | $27.9M | $30.3M | $50.9M | $14.2M | $16.9M |
| Total assets | $66.7M | $72.0M | $73.3M | $79.1M | $128.6M | $62.5M | $22.9M | $36.9M |
| Total liabilities | $2.8M | $5.4M | $11.6M | $11.2M | $20.4M | $6.8M | $9.9M | $25.9M |
| Shareholders' equity | $63.9M | $66.6M | $61.7M | $68.0M | $108.3M | $55.7M | $13.0M | $11.0M |
Growth · year-over-year · Revenue CAGR 50920.4%
| Metric | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| Revenue growth | — | — | — | — | +50920.4% | — | — | — |
Each column is the change versus the prior fiscal year. Growth off a negative or zero base is shown as “—”. CAGR is the compound annual revenue growth across the years shown.
Computed from company filings · US · as of 2026-03-31. Facts plus Stocktoria's own computed scores — not investment advice.